Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm Open-label Phase II Trial to Assess the Efficacy and Safety of Pembrolizumab for Unresectable Advanced or Recurrent Ovarian Squamous Cell Carcinoma

NCT05737199 is registered in ClinicalTrials.gov with Niigata University Medical & Dental Hospital as lead sponsor.

NCT NCT05737199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05737199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm Open-label Phase II Trial to Assess the Efficacy and Safety of Pembrolizumab for Unresectable Advanced or Recurrent Ovarian Squamous Cell Carcinoma
Lead sponsor
Niigata University Medical & Dental Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 1, 2023
Completion date
May 31, 2028
Enrollment
21 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian squamous cell carcinoma